Insights into disease-associated tau impact on mitochondria by Szabo, Leonora et al.
 International Journal of 
Molecular Sciences
Review
Insights into Disease-Associated Tau Impact
on Mitochondria
Leonora Szabo 1,2, Anne Eckert 1,2 and Amandine Grimm 1,2,3,*
1 Neurobiology Lab for Brain Aging and Mental Health, Transfaculty Research Platform,
Molecular & Cognitive Neuroscience, University of Basel, 4002 Basel, Switzerland;
leonora.szabo@unibas.ch (L.S.); anne.eckert@unibas.ch (A.E.)
2 Psychiatric University Clinics Basel, 4002 Basel, Switzerland
3 Live Sciences Training Facility, Division of Molecular Psychology, University of Basel,
4055 Basel, Switzerland
* Correspondence: amandine.grimm@unibas.ch; Tel.: +41-61-325-5347; Fax: +41-(0)-61325-55-77
Received: 9 July 2020; Accepted: 28 August 2020; Published: 1 September 2020


Abstract: Abnormal tau protein aggregation in the brain is a hallmark of tauopathies, such as
frontotemporal lobar degeneration and Alzheimer’s disease. Substantial evidence has been linking
tau to neurodegeneration, but the underlying mechanisms have yet to be clearly identified. Mitochondria
are paramount organelles in neurons, as they provide the main source of energy (adenosine triphosphate) to
these highly energetic cells. Mitochondrial dysfunction was identified as an early event of neurodegenerative
diseases occurring even before the cognitive deficits. Tau protein was shown to interact with mitochondrial
proteins and to impair mitochondrial bioenergetics and dynamics, leading to neurotoxicity. In this review,
we discuss in detail the different impacts of disease-associated tau protein on mitochondrial functions,
including mitochondrial transport, network dynamics, mitophagy and bioenergetics. We also give new
insights about the effects of abnormal tau protein on mitochondrial neurosteroidogenesis, as well as on
the endoplasmic reticulum-mitochondria coupling. A better understanding of the pathomechanisms of
abnormal tau-induced mitochondrial failure may help to identify new targets for therapeutic interventions.
Keywords: tau protein; mitochondria; tauopathies
1. Introduction
The brain is a high-energy consuming organ and requires a remarkable 20% of the body’s energy
to fulfill its functions. In order to meet this high energy demand, neuronal cells strongly rely on
the proper performance of the oxidative phosphorylation system (OXPHOS) of mitochondria [1].
Accordingly, the maintenance of proper mitochondrial function is of utmost importance for functional
energy production and consequently the viability of neurons [2]. Thus, long-lasting disturbances
may induce various pathologies, ranging from subtle alterations in neuronal function to cell
death and neurodegeneration [1]. Therefore, mitochondrial dysfunction seems to be a hallmark
of neurodegenerative disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and
Huntington’s disease (HD), and was observed already at early disease stages, before the onset of
cognitive impairments [3,4].
Tau protein belongs to the family of microtubule-associated proteins (MAPs) that stabilize
microtubule assembly and function (reviewed in [5]). Tau is expressed in most neurons and
plays a role in axonal transport, cell polarity, and neurotransmission. Tau is also involved in
the pathophysiology of neurodegenerative disorders called tauopathies that are characterized by an
aberrant intracellular accumulation of tau within neurons, abnormal tau hyperphosphorylation and
assembly into neurofibrillary tangles (NFTs). In primary tauopathies, such as frontotemporal lobar
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degeneration (FTLD), Pick’s disease, corticobasal degeneration (CBD), progressive supranuclear palsy
(PSP), and sporadic multiple system tauopathy, tau plays a primary role and mutant forms of tau
proteins were identified [5]. In secondary tauopathies, such as AD, Creutzfeldt–Jakob disease and
Chronic Traumatic Encephalopathy (CTE), tau plays also a role in the pathogenesis of the disease but
other major factors are involved, as, for instance, amyloid-β (Aβ) accumulation in AD. Substantial
evidence has been linking abnormal tau to neurodegeneration, but the mechanisms underlying
tau-induced neuronal dysfunction and death are still incompletely understood.
Mounting evidence highlights the dysfunction of mitochondria in tauopathies, including reduced
bioenergetics as well as abnormal mitochondrial morphology [6,7]. Besides, abnormal tau has
many effects on other cellular functions that may lead to neurodegeneration, which are nicely
reviewed elsewhere [8–10]. In the present review, we aim to give insights about tau impacts on
the different functions of mitochondria in order to draw a “mitocentric” picture of tau toxicity.
First, we summarize what is known about tau protein structure and function in health and disease.
Then, we remind important aspects of mitochondrial function in order to better apprehend the
impact of tau on this paramount organelle. Finally, we discuss how disease-associated tau disturbs
mitochondrial functions, including recent developments from the past five years, as well as new
insights about abnormal tau effects on mitochondrial neurosteroidogenesis and the endoplasmic
reticulum (ER)-mitochondria coupling.
2. Tau Protein
2.1. Tau Structure and Domains
In the human genome, tau proteins are encoded by a single gene, the microtubule-associated protein
tau (MAPT) gene, which comprises 16 exons located on chromosome 17q21 [5,11–14]. Alternative
splicing of exons 2, 3 and 10 results in the expression of six different isoforms (2N4R, 1N4R, 0N4R,
2N3R, 1N3R, 0N3R) that are all present in the adult human brain. These splicing variants differ from
each other in the presence of zero, one or two N-terminal inserts (0N, 1N or 2N, respectively) and in the
number of either three (3R) or four (4R) microtubule-binding repeats in the C-terminal part [10,11,13,15].
While the six isoforms appear to be broadly functionally similar, each is likely to have specific and
partially distinctive physiological roles. Of particular interest are the splicing products of exon 10,
the 3R and 4R isoforms, normally being expressed in a one-to-one ratio in most regions of mature
brains [16,17]. However, deviations from this ratio are associated with certain tauopathies, which can
be classified into three groups (3R, 4R or 3R/ 4R) depending on the isoforms found in pathogenic
aggregates, and thereby facilitating the onset of the disease [18]. Specifically, compared to 3R tau,
4R tau exhibits a higher affinity for microtubules, and is consequently more efficient in promoting
microtubule assembly [10,19]. Interestingly, the two isoforms also seem to impact the motor function
of microtubules differentially. Whereas 4R tau decreases the localization of mitochondria to axons to a
greater extent than 3R tau, the 3R isoforms are more efficient in increasing the percent of mitochondria
moving in the retrograde direction [5,20]. Besides, depending on the isoform tau contains either one or
two cysteine residues in the microtubule-binding domain. While in the 3R isoform only C322 within
the third repeat is present, 4R tau additionally comprises C291 within the fourth repeat. This variance
seems to have an influence on the assembly of paired helical filaments (PHFs) in vitro [21].
The structural basis of tau to bind its interaction partners and to perform its functions lies in
the organization of tau’s amino acid sequence. Depending on the biochemical properties, tau can be
subdivided into the N-terminal projection domain, the proline-rich region, the microtubule-binding
domain and the C-terminal region [22–24]. When bound to microtubules, the N-terminal domain
of tau projects away from the microtubule surface, where it is believed to interact with components
of the neuronal plasma membrane [25,26]. Moreover, this region is involved in determining the
spacing between microtubules [11,22,27]. The proline-rich region instead harbors PXXP motifs that
provide potential recognition sites for SH3 domain-containing proteins of the Src family kinases,
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such as Fyn, playing a role in signal transduction [22,26,28]. Furthermore, the ability of tau to
interact with microtubules is mediated by the microtubule-binding domain in combination with the
adjacent proline-rich flanking domains. Whereas the microtubule-binding repeats bind only weakly to
microtubules (but possess specificity for microtubule assembly), the proline-rich region provides an
efficient targeting to the microtubule surface [29,30].
Tau is a highly soluble, natively unfolded protein that maintains a highly flexible conformation
and overall has little secondary structure [31]. However, when binding to interacting proteins and
partners, tau may form local conformations [29]. Furthermore, it has been proposed that soluble
tau preferentially changes its global conformation to a paperclip structure, where the C-terminal
region folds over the microtubule-binding domain and the N-terminal region folds back over of the
C-terminal one, placing them in close proximity [32]. This paperclip fold formation might protect
tau from aggregation [33]. Truncated tau has a higher tendency for aggregation [34], which could be
probably due to the disruption of the paperclip structure [33].
2.2. Post-Translational Modifications
Besides alternative splicing, tau is a subject of numerous post-translational modifications that highly
regulate the functions of tau in both physiological and pathological conditions. The most commonly
described post-translational modification of tau is phosphorylation. Tau is a phosphoprotein containing
85 potential phosphorylation sites on the longest tau isoform consisting of 45 serine, 35 threonine
and 5 tyrosine residues [5,35,36]. Tau phosphorylation is developmentally regulated with fetal tau
experiencing higher levels of modification than adult tau [37]. The normal phosphorylation state of
tau is a consequence of the dynamic regulation between the activities of a large number of protein
kinases and phosphatases [22,38]. Many different kinases have been demonstrated to be involved
in the site-specific phosphorylation of tau. Tau phosphorylating kinases include, among others,
the glycogen synthase kinase (GSK) 3α/ β, cyclin-dependent kinase 5 (Cdk5), mitogen-activated
protein kinases (MAPKs), tau-tubulin kinase 1/2 (TTBK1/ 2), cAMP-dependent protein kinase A (PKA),
protein kinase C (PKC), 5′ adenosine monophosphate-activated protein kinase (AMPK), calcium/
calmodulin-dependent protein kinase II (CaMKII), and finally tyrosine kinases of the Src family like
Src, and Fyn [39]. Of those, GSK 3β and Cdk5 are especially supposed to play a relevant role in the
pathogenesis of tauopathies like AD, contributing to increased phosphorylation [23,40]. Conversely,
several protein phosphatases including protein phosphatase 1 (PP1), PP2A, PP2B, PP2C and PP5
have been implicated in tau de-phosphorylation [38]. Among them PP2 is considered as the main
phosphatase, accounting for approximately 70% of the total tau phosphatase activity in the brain.
Moreover, it was demonstrated that PP2 activity is 50% decreased in AD brains, thus leading to increased
phosphorylation of tau [41]. While tau phosphorylation traditionally has been the most intensively
studied post-translational tau modification, tau is likewise a target of many other post-translational
modifications, including acetylation, glycosylation, glycation, deamidation, prolyl-isomerisation,
nitration, sumoylation, methylation, ubiquitination, and truncation (reviewed in [5,22]). Together,
these modifications differentially regulate the functions of tau and may as well influence one
another. Nevertheless, in contrast to the more investigated role of phosphorylation in tau pathology,
the implication of the other tau post-translational modifications is yet to be fully characterized.
2.3. Physiological Functions of Tau
Tau is considered as a multi-functional protein that plays a number of different roles in neuronal
cells. In the adult human brain, tau is predominantly distributed in the axons of neurons [11,42]. There,
one of tau’s primary functions is to bind microtubules, where this interaction promotes microtubule
assembly and thereby modulates their stability [5,43]. Remarkably, physiologically more than 90%
of tau is attached to microtubules [44]. This ability of tau to bind microtubules is mediated by
KXGS motifs within the microtubule-binding domain and proline-rich flanking domains [45,46].
While microtubule-binding repeats attach to the inner face, the flanking regions interact with the
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surface of microtubules [47]. Under physiological conditions, binding of tau to microtubules is a
highly dynamic process that is dependent on several factors, including tau isoforms, mutations,
post-translational modifications, but also the method used to determine the interaction between tau and
microtubules [23]. Concerning the influence of post-translational modifications, this binding ability is
most prominently regulated by tau’s phosphorylation state [35,48]. Kinase-mediated phosphorylation
of tau detaches the protein from microtubules and subsequently causes their depolymerization,
whereas phosphatases de-phosphorylate tau and retain the binding ability to microtubules [49].
Especially the phosphorylation of the KXGS motifs within the microtubule-binding domain has
been shown to strongly reduce the binding ability of tau to microtubules [36,50]. Frequent cycles
of binding and detachment of tau from microtubules are not only important for the regulation of
microtubule stability, but consequently affect the maintenance of effective axonal transport [36].
Axonal transport is a critical process in neurons required for the efficient movement of organelles,
lipids, proteins, nucleic acids, and synaptic vesicles. Microtubules provide the platforms for proper
intracellular transport by allowing motor proteins to interact with them [51]. While kinesins transport
cargoes in the anterograde direction, dyneins are carrying cargoes in the retrograde direction [52].
Upon microtubule binding, tau is involved in the regulation of axonal transport, where tau modulates
the motility of kinesin and dynein. When encountering microtubule-bound tau dynein tends to reverse
direction, whereas kinesin detaches at patches of bound tau in a concentration- and isoform-dependent
manner [53]. Moreover, tau binds to the p150 subunit of dynactin, which stabilizes the interaction of
dynein with microtubules, and thus supports dynein-dependent axonal transport [54]. Since axonal
transport of cargoes, like mitochondria, to different parts of neurons is essential for a proper synaptic
function, pathological changes of tau may lead to the impairment of this transport [55]. In addition to
these well-known functions, tau was also found to interact with the actin cytoskeleton. Tau protein
may bind to filamentous actin to induce aligned bundles of actin filaments, therefore modifying
the organization of the cytoskeleton network [5,56]. To note, physiologically a small amount of tau
distributes as well in dendrites. However, the physiological function of dendritic tau has not been
well elucidated. Nonetheless, it has been proposed that tau has a dendritic role in the post-synaptic
targeting of the Fyn kinase [57,58], where it binds Fyn through PXXP motifs within its proline-rich
region and thus promotes the recruitment of Fyn to NMDA receptors [58,59]. The targeting of tau to
the post-synapse may play a role in mediating synaptic plasticity, especially long-term depression [60]
and hence memory formation [61]. Besides, in axons and dendrites, tau has additionally been detected
in the nucleus. Nuclear tau appears to be involved in protecting the integrity of genomic DNA,
nuclear RNA and cytoplasmic RNA, thus ensuring their functionality and longevity [62–64].
2.4. Pathological Aggregation of Tau
Under pathological conditions, alterations in the properties of tau may lead to its aggregation
that is characteristic of several neurodegenerative diseases. The conversion of physiologic soluble
tau species into pathologic fibrillary tau aggregates is considered to be a multi-step process [11].
As one of the mechanisms to drive tau aggregation aberrant phosphorylation has been assumed,
since hyperphosphorylation and aggregation of tau are both increased in AD [65]. Hyperphosphorylation
of tau is most likely to result from an imbalance in the activities of specific tau kinases
and phosphatases, causing an increased rate of tau phosphorylation and/ or decreased rate of
de-phosphorylation [66]. Consequently, tau hyperphosphorylation reduces its binding affinity to
microtubules, thereby induces a loss of tau’s normal microtubule-stabilizing function [67,68], and thus
causes microtubule depolymerization [49]. Specifically, the phosphorylation of KXGS motifs within the
microtubule-binding domain (in particular S262) and S214 within the flanking region of tau have been
described to strongly decrease the affinity of tau for microtubules [69,70]. Furthermore, in vitro studies
demonstrated that phosphorylation of T231 within the flanking region also contributes to the reduced
binding of tau to microtubules [71]. The detachment of tau from microtubules subsequently leads to
an abnormal increase of free unbound tau in the cytosol [72]. This higher cytosolic concentration
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may render tau substantially more likely to undergo misfolding. Thereafter, as an early pathological
event, non-fibrillar tau deposits, referred to as pre-tangles, are formed. Following steps comprise
conformational changes leading to the generation of PHFs. This transition from pre-tangles to PHFs
includes the formation of characteristic β-sheet-like structures [11,73]. Precisely, the hexapeptide
motifs PHF6 and PHF6* located in the second and third microtubule-binding repeats exhibit a high
β-sheet propensity, and are supposed to promote abnormal tau aggregation in vitro and in cell and
animal models [22,23,26]. Finally, PHFs further self-assemble to form more organized aggregates,
and eventually develop insoluble NFTs inside neurons. The following sequestration of NFTs together
with compromised cytoskeleton dynamics impairs normal axonal transport, and hence contributes
to synaptic dysfunction and neurodegeneration [74,75]. In addition, alterations of tau itself, such as
mutations in the MAPT gene, can also contribute to tau aggregation. For instance, in the tau mutations
P301L, P301S and ∆K280 that are found in frontotemporal dementia with parkinsonism-17 (FTDP-17)
the hexapeptide motif PHF6* is present. As a result of this enhanced β-sheet propensity, tau with these
mutations tends to have a decreased affinity for microtubules and an increased ability to assemble into
filaments, thus promoting tau aggregation [22,30,76]. To point out, even though phosphorylation of
S262 and S214 strongly prevents the attachment of tau to microtubules, phosphorylation of these sites
tends to inhibit PHF formation [21].
Although tau phosphorylation is frequently considered as one of the most important modifications
leading to aggregation, emerging evidence has related N-terminal truncated tau to tau pathology.
In fact, several specific truncations of tau have been identified in AD brains. Moreover, studies
demonstrated that proteolytic cleavage of tau at N368, D421 and E391 increases its susceptibility
to form NFTs [33,77]. Despite intense investigation, the precise pathogenesis of tau-mediated
neurodegeneration in tauopathies still remains unclear. Although the accumulation of insoluble
aggregated tau deposits in form of NFTs is considered as a pathological hallmark of tauopathies [78]
with their regional distribution correlating with the severity of the cognitive decline in AD brains [79],
the neurotoxicity of NFTs per se is controversial. Instead, recent evidence indicates that small
soluble oligomeric forms of tau, generated during tangle formation, are the most toxic tau species
causing neuron damage and synaptic dysfunction [80]. However, the toxic gain of function by
NFTs might contribute to the disease progression as well [16]. Of note, increasing evidence has
been linking tau pathology and neuroinflammation. Indeed, abnormal tau was associated with
reactive microglia, as well as increased levels of pro-inflammatory cytokines (e.g., interleukin-1β) and
complement proteins (reviewed in [81]). The chronic neuroinflammation may lead to synapsic loss
and cognitive decline. Interestingly, microglial cells themselves seem to be involved in the spreading
of tau pathology [82].
Current therapeutic strategies targeting tau consist of anti-aggregation agents (regulation of
tau phosphorylation, inhibition of tau aggregation), tau passive immunotherapy, tau therapeutic
vaccines, targeting of tau gene expression (antisense therapies) and therapeutic reduction of tau
(reviewed in [83]). Strikingly, the effects of tau-targeting drugs on mitochondrial function remain
underinvestigated. Conversely, evidence showed that improving mitochondrial quality control via
activation of mitophagy (removal of damaged mitochondria, see Section 3.2.) decreases tau pathology
in different experimental models (reviewed in [84]). Namely, nicotinamide riboside supplementation
(activator of mitophagy) was shown to decrease abnormal tau phosphorylation, neuroinflammation
and cognitive impairments in AD transgenic animals [85,86]. Of note, mitophagy itself seems to play
also a role in the regulation of the inflammatory response [87]. Further studies need to be performed to
unravel the role of mitophagy in the reduction of tau pathology via modulation of neuroinflammation.
To our knowledge, only one of the tau-targeting agents undergoing clinical trials was shown to
also have an effect on mitochondria [88]. Indeed, methylene blue (MB), also known as methylthionine
chloride (MTC), is already an approved drug against malaria, and acts as a direct inhibitor of tau
protein aggregation [83]. MTC was shown to counteract oxidative stress-induced mitochondrial
damage, and to inhibit the monoamine oxidase A that is a source of reactive oxygen species (ROS) [88].
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Despite the improvements observed in AD-related symptoms during phase II clinical trials, too many
undesirable side effects were reported (e.g., dizziness, diarrhoea, painful urination) for the drug to be
used (Clinical Trial Identifier, NCT00515333 and NCT00684944) [83].
3. Mitochondria
Mitochondria are complex cytosolic organelles in eukaryotic cells that have been known for over
a century. Unlike other organelles, they are maternally inherited (although biparental inheritance
of mitochondrial DNA was recently reported but still under debate [89,90]) and compartmentalized.
Concerning their structural characteristics, mitochondria consist of a matrix and two membranes
with an interjacent intermembrane space (IMS). The outer mitochondrial membrane (OMM) smoothly
envelops and separates the organelle from the cytosol, whereas the inner mitochondrial membrane
(IMM) is tightly folded, forming multiple invaginations termed as cristae. These organelles play
a pivotal role in cell survival and death by regulating both energy metabolism and apoptotic
pathways. Additionally, they contribute to an array of cellular functions, including intracellular
calcium homeostasis, reduction-oxidation (redox) signaling, innate immunity, steroid biosynthesis and
synaptic plasticity, to name a few [91,92]. In the following paragraphs, we will introduce key aspects
of mitochondrial physiology that are relevant to understand the deleterious impact of abnormal tau on
this paramount organelle (described in Sections 4 and 5).
3.1. Mitochondrial Bioenergetics
Despite this diversity of functions, mitochondria remain best known as the main source of
cellular energy production in the form of adenosine triphosphate (ATP) via OXPHOS. OXPHOS refers
to the metabolic process in which electrons are transferred stepwise to oxygen through a series of
redox reactions between protein complexes to ultimately drive the synthesis of ATP. These protein
complexes are embedded in the IMM and comprise four biochemically linked multi-subunit complexes
(Complexes I, II, III and IV), known as the electron transport chain (ETC), and the ATP synthase
(Complex V) [93]. Briefly, enzymes of the tricarboxylic acid cycle within the mitochondrial matrix
oxidize acetyl-CoA, which is derived from carbohydrates, fats and proteins, to generate the reducing
equivalents nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) [94].
Subsequently, these molecules pass their electrons to the ETC. The following oxidation of these reduced
substrates causes conformational changes in the respiratory chain Complexes I, III and IV, allowing
them to pump protons (H+) out of the mitochondrial matrix into the IMS [95]. This in turn, produces
a proton-gradient and thereby establishes an electrochemical potential, termed as mitochondrial
membrane potential (∆Ψm) [2]. As a result, Complex V utilizes this proton motif force to catalyze the
synthesis of ATP by phosphorylating adenosine diphosphate (ADP) [96] (Figure 1).
Although the physiological functions of mitochondria, such as the production of energy, are critical
for cell survival, they also induce the formation of ROS that can pose serious damage to cells when
generated in excess [1]. In order to avoid exceeding levels of ROS, cells possess efficient antioxidant
mechanisms that scavenge ROS to non-toxic forms [97]. Consequently, under physiological conditions,
the production and detoxification of ROS are balanced. However, an increased ROS production
and/or a reduced antioxidant system can induce oxidative stress, which in turn damages proteins and
DNA, and initiates lipid peroxidation. Since long polyunsaturated fatty acids chains of mitochondrial
membranes exhibit a high susceptibility to oxidation, mitochondria represent the first targets of ROS
toxicity, leading to depolarized membranes and damaged proteins, and consecutively to mitochondrial
impairments. As a result, oxidative stress-induced mitochondrial dysfunction may initiate cell death,
and has been implicated in the pathogenesis of many neurodegenerative diseases, including AD [1,98,99].
Namely, mitochondria-derived oxidative stress was proposed to be a causative factor for Aβ and tau
pathology [1,98,100]. Indeed, Aβ load was increased in cells and mice that produced more ROS due
to a mitochondrial Complex I inhibition/ deficiency [101]. Similarly, increased levels of tau and tau
phosphorylation (at S396, S404, T205, T231) were observed in mice lacking the detoxifying enzyme
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superoxide dismutase 2 (SOD2) [102]. This suggests that mitochondrial dysfunction, more precisely
mitochondria-derived ROS, might be involved in the pathogenesis of tauopathies.
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Figure 1. Schematic representation of oxidative phosphorylation (OXPHOS) in mitochondria.
The process of OXPHOS is the main pathway in the cell to produce adenosine triphosphate (ATP).
It consists of two coupled processes embedded in the inner mitochondrial membrane (IMM), the electron
transport chain (ETC) and the ATP synthesis. In the ETC, the reduced substrates NADH and FADH2
are oxidized by the NADH-ubiquinone oxidoreductase (Complex I) and succinate-CoenzymeQ
reductase (Complex II), respectively. These proteins transfer electrons from their substrates onto Q-10,
which serves as a substrate for the CoenzymeQ-cytochrome c oxidoreductase (Complex III). Q-10 is a
highly lipophilic substance that is able to diffuse within the IMM. Complex III transfers the electrons
from Q-10 onto cytochrome c, which is a water-soluble electron carrier, located at the surface of the
IMM in the IMS. In the final step of the ETC, cytochrome c oxidase (Complex IV) uses the electrons
from reduced Cyt c to reduce molecular oxygen to water. In the process of transferring electrons,
the Complexes I, III and IV actively move protons (H+) from the mitochondrial matrix to the IMS,
forming the ∆Ψm. Ultimately, this potential is used by the ATP synthase (Complex V) to catalyze
the generation of ATP from ADP and Pi. ADP: adenosine diphosphate, ATP: adenosine triphosphate,
Cyt c: cytochrome c, ETC: electron transport chain, FADH2: flavin adenine dinucleotide, IMM: inner
mitochondrial membrane, IMS: intermembrane space, NADH: nicotinamide adenine dinucleotide, Pi:
inorganic phosphate, Q-10: coenzymeQ10, ∆Ψm: mitochondrial membrane potential.
3.2. Mitochondrial Dynamics
As commonly known, mitochondria are highly dynamic organelles that form a remarkably complex
interconnected network, which varies greatly in different cell types. In response to external and internal
stimuli, mitochondria are therefore able to adapt rapidly the degree to which they are networked [103].
Concretely, mitochondrial dynamics results from the interplay of processes, including mitochondrial
biogenesis, mitochondrial fusion and fission, mitophagy, and mitochondrial trafficking (Figure 2).
These processes maintain the mitochondrial homeostasis and regulate mitochondrial morphology and
their distribution, ultimately being a vital component of the cellular stress response [104].
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of PINK1 and the subsequent recruitment of Parkin target defective mitochondria that are subsequently
deg aded by mitophagy. DRP1: ynamin- lated protein 1, FIS1: mitochondri l fission protein 1, IMM:
inner mitocho drial me brane, MFN1: mitofusin 1, MFN2: mitofusin 2, OMM: oute mitochondrial
membrane, OPA1: optic atrophy 1, PINK1: PTEN-induced kinase 1.
The morphology of the cellular mitochondrial network is sustained by continuous rounds of fusion
and fission. Consequently, the balance betwee these two pposite processes modulates mitochondrial
number, shape and size [105]. While increased fusion generat elongated, int rconnect d itochondria,
enhanced fission promotes mitochondrial fragmentation. This plastic adaptation is particularly essential
in neurons that are highly polarized cells. Since axons and dendrites have differential energy demands,
the regulation of fusion and fission produces a generally more elongated network in the somatodendritic
compartment and a more fragmented one in axons [106]. Notwithstanding, the mitochondrial integrity
is fundamental for the mitochondrial metabolic activity and mitochondrial health. For instance, in fused
organelles, the efficiency of ATP production is increased and the exchange of matrix content—including
mitochondrial DNA—is favored. Fragmented organelles, in contrast, produce more ROS and are
readily cleared by mitophagy. Nevertheless, mitochondrial fragmentation is indispensable during cell
division for the equal distribution of mitochondria to daughter cells [107].
In mammalian cells, mitochondrial fusion involves the actions of three large dynamin-related
guanosine triphosphatases (GTPases). While mitofusin 1 (MFN1) and 2 (MFN2) are the key mediators of
the OMM fusion, optic atrophy 1 (OPA1) mediates the fusion of the IMM. Of note, OPA1 also regulates
the remodeling of mitochondrial cristae, which is implicated in processes such as apoptosis [108].
Conversely, mitochondrial fissi n in mammalian cells is primarily orchestrated by dynamin-related
protein 1 (DRP1), which is also a GTPase. In order to initiate mitochondrial fission, DRP1 needs to be
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recruited from the cytosol to mitochondria. This translocation depends on its phosphorylation state at
S637. Whereas PKA-mediated phosphorylation of S637 retains DRP1 in the cytoplasm, Ca2+-dependent
phosphatase calcineurin de-phosphorylation targets DRP1 to the OMM. This has been described to
occur preferentially at regions associated with the ER. Subsequently, DRP1 oligomerizes into ring-like
structures around mitochondria, providing the required mechanical fission force. As a consequence,
guanosine triphosphate (GTP) hydrolysis induces membrane constriction, and thus facilitates scission.
A series of additional proteins have been presented to recruit and assemble DRP1, and therefore assisting
in the complete separation of mitochondria, including mitochondrial fission factor (MFF), mitochondrial
dynamics protein 49 and 51 (MiD49/ 51), and mitochondrial fission 1 protein (FIS1). Although FIS1 was
formerly identified as an essential regulator of mitochondrial fission, recent studies demonstrated that
it appears to be dispensable for physiological fission. However, FIS1 may be involved in pathological
fission processes. Since mitochondrial fusion and fission are crucial for the maintenance of cell survival,
a pathological imbalance is associated with many disorders, such as neuropathies, brain injury, extreme
stress conditions, aging, and neurodegenerative diseases [105,107,109]. Unsurprisingly, an altered
balance of these processes has been reported in AD, both on transcript and protein levels [110,111].
Beyond mitochondrial fusion and fission, another fundamental aspect involved in mitochondrial
dynamics includes the regulation of mitochondrial trafficking. The proper subcellular distribution
of mitochondria in neuronal cells is indispensable for ATP provisioning, axonal growth promotion,
calcium buffering, and to ensure mitochondrial repair and degradation. In mammals, mitochondrial
transport is mediated via the activities of the motor proteins dynein and kinesin, which are associated
with the adaptor and receptor proteins of the OMM. Precisely, the transmembrane receptor protein
mitochondrial Rho GTPase (Miro) interacts with the adaptor protein Milton that in turn tethers to
motor proteins. Notably, when production of ATP and calcium buffering are required at specific sites,
mitochondrial movement can be halted, and thus mitochondria are retained [112,113]. Accordingly,
a loss of this Miro-Milton-dependent transport may cause depletion of mitochondria in dendrites and
axons, giving arise to neurotransmission defects [114].
Equally important to fusion and fission, mitochondrial biogenesis and mitophagy regulate the
dynamics of mitochondria. The balanced action of these two opposing cellular pathways determines the
mitochondrial mass and accurate turnover, and is thus crucial for maintaining a healthy mitochondrial
pool. Hence, the tight coordination of mitochondrial biogenesis and degradation is essential for
the cellular adaptation in response to the cellular metabolic state, stress, and other intracellular
or environmental signals [115,116]. During mitochondrial biogenesis, mitochondria increase their
individual mass and copy number in order to either elevate mitochondrial function in general, or to
compensate for decreased mitochondrial mass, resulted from higher rates of degradation. Damaged or
energy-deficient mitochondria can be selectively degraded via mitochondrial autophagy, a process
termed mitophagy. One of the best-characterized mitophagy pathways involves the operations of
the proteins PTEN-induced kinase 1 (PINK1) and Parkin. The process of mitophagy is initiated,
when dysfunctional fractions of the mitochondrial network cause a loss in ∆Ψm. Although PINK1 is
normally imported and degraded within the organelle, this depolarization results in the accumulation
of PINK1 in the OMM. Accumulated PINK1 has been shown to phosphorylate ubiquitin in the
OMM, consequently leading to the recruitment of the cytosolic ubiquitin ligase Parkin to the surface
of mitochondria. Following translocation, activated Parkin ubiquitinylates proteins of the OMM.
Subsequently, impaired mitochondria are recognized and engulfed into the autophagosome, ultimately
targeted for lysosomal degradation [113,117]. Given the pivotal role of mitophagy in maintaining
mitochondrial quality control and homeostasis, unsurprisingly, suppression or abnormalities of this
process may result in the accumulation of damaged mitochondria. Indeed, mitochondrial dysregulation
with regard to mitophagy has been implicated in several neurodegenerative diseases, including PD,
AD, and HD. Recent findings in AD patients with sporadic late-onset AD emphasized that mitophagy
is compromised, leading to the accumulation of dysfunctional mitochondria, and thus contributing to
synaptic dysfunction and cognitive deficits [118].
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4. Mitochondria: Target of Tau
Abnormal tau impairs mitochondrial function, leading to neuronal degeneration, but the exact
mechanisms are still not completely understood. In this section, we will discuss different impacts of
abnormal tau on mitochondria in order to draw a “mitocentric” picture of tau toxicity. Noteworthy,
nearly all the data discussed here derived from in vitro and animal studies. Therefore, studies performed
on patients with tauopathies are highly needed, in order to confirm and fully apprehend mitochondrial
dysfunctions induced by abnormal tau protein.
Important mitochondrial impairments observed in the presence of abnormal tau are summarized
in Table 1 and Figure 3.
Table 1. Impacts of tau on mitochondrial function in vitro and in vivo.
Mitochondrial
Function Model
Main Impairments in the Presence of Abnormal Tau
Versus Respective Controls Reference
Transport
K3 mice
(human K369I mutant tau)
Impairment in anterograde (not retrograde) transport of




Decreased percentage of the cytoplasm occupied by
mitochondria
Reduction of mitochondrial content in neurites
Perinuclear clustering of mitochondria with no change
in mitochondrial volume
[120]
PC12 cells and cortical neurons
expressing tau mutants: 3A
(non-phosphorylatable) and 3D
(phosphorylation mimic), with
mutations at the AT8 sites (S199,
S202, and T205)
Increase in stationary mitochondria, decrease in the
velocity of mitochondrial movement
Increase in the inter-microtubular spacing affecting
mitochondrial movement
[121]
KI-P301L mice (P301L tau knock-in)
Reduced number of axonal mitochondria
Increased volume of motile mitochondria in the axons
Impaired binding of tau to microtubules
[122]
IPSC-derived neurons with tau
mutations
Reduced number of axonal mitochondria and increase
retrograde transport (IPSCs with R406W tau mutation)
Decreased anterograde transport (IPSCs with N279K




wild-type tau or human R406W
mutant tau
rTg4510 and K3 mice
Excessive mitochondrial elongation
Increased actin stabilization and decreased localization
of dynamin-related protein 1 (DRP1) to mitochondria
[125]
HEK293 cells and rat primary
hippocampal neurons expressing





Disruption of mitochondrial dynamics, enhanced fusion
and perinuclear accumulation of mitochondria
Increased expression of fusion proteins mitofusin 1
(MFN1), mitofusin 2 (MFN2) and optic atrophy 1
(OPA1), reduced ubiquitination of MFN2
[126]
SH-SY5Y cells stably overexpressing
wild-type (wt) and P301L
mutant tau
Changes in mitochondrial morphology, decreased fusion
and fission rates





(human P301L mutant tau)
Decreased mitochondrial respiration, mitochondrial
Complex I activity, adenosine triphosphate (ATP) levels
Increased reactive oxygen species (ROS) levels and
superoxide anion radicals (O2•−)
[128,129]
SH-SY5Y cells stably overexpressing
wild-type (wt) and P301L
mutant tau
Decreased mitochondrial respiration, mitochondrial




HEK293 cells expressing the human
wild-type full-length tau (hTau)
hTau mice
Decreased mitochondrial Complex I activity, ATP levels,
and ATP/ ADP ratio [126]
mPTP Three-months-old tau knockout(tau-/-) mice
Inhibition of mitochondrial permeability transition pore
(mPTP) formation in the hippocampus, reduction of
cyclophilin D (CypD) protein level
[132]




Main Impairments in the Presence of Abnormal Tau





Increase of mitophagy markers (COX IV, TOMM20, ratio
mtDNA/ nDNA)
Dose-dependent allocation of tau proteins into the outer
mitochondrial membrane (OMM)
Increased ∆Ψm, which impairs the mitochondrial
residence of PTEN-induced kinase 1 (PINK1)/ Parkin
[133]
N2a cells and Caenorhabditis
elegans expressing human
wild-type (hTau) and P301L
mutant tau
Decreased mitophagy
Sequestration of Parkin in the cytosol, preventing its





overexpressing wild-type (wt) and
P301L mutant tau
Decreased pregnenolone synthesis [131]
AD: Alzheimer’s disease, COX IV: cytochrome c oxidase subunit IV, FTD: frontotemporal dementia, IPSCs: induced
pluripotent stem cells, TOMM20: translocase of outer mitochondrial membrane 20, mtDNA/ nDNA: mitochondrial
DNA/ nuclear DNA.
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SH-SY5Y cells stably 
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Figure 3. Abnormal tau protein impairs mitochondrial function. The scheme summarizes the impact 
of disease-associated tau protein on the different aspects of mitochondrial function (see details in the 
text). Of note, the effects illustrated here may be different according to tau models used (phospho-tau 
versus truncated tau). (1) Abnormal tau inhibits anterograde transport of mitochondria along the 
axon, leading to a decreased number of mitochondria at the synapse, and mitochondrial perinuclear 
clustering. (2) Abnormal tau seems to trigger mitochondrial network elongation by increasing MFN2 
levels and by triggering DRP1 mislocalization and clustering in actin filaments. (3) Abnormal tau 
inhibits mitophagy by interacting with Parkin. (4) Abnormal tau disturbs mitochondrial bioenergetics 
by inhibiting Complex I activity, decreasing the ΔΨm and ATP levels, and increasing ROS 
production. These effects may also be linked to abnormal tau impacts on the mPTP opening, and/ or 
to tau direct binding on mitochondrial proteins like voltage-dependent anion channel (VDAC) and 
subunits on the respiratory Complex V. (5) Abnormal tau disturbs mitochondrial steroidogenesis by 
Figure 3. Abnormal tau protein impairs itochondrial function. The scheme sum arizes the impact of
disease-associated tau protein on the different aspects of mitochondrial f nction (see details in the text).
Of note, the effects illustrated here may be different according to tau odels used (phospho-tau versus
truncated tau). (1) Abnormal tau inhibits antero rade transport f mitochondria long the axon, leading to a
decreased number of mitochondria at the synapse, and mitochondrial perinuclear clustering. (2) Abnormal
tau seems to trigger mitochondrial network elongation by increasing MFN2 lev l and by triggering DRP1
mislocalization and clustering in actin filaments. (3) Abnormal tau inhibits mitophagy by interacting
with Parkin. (4) Abnormal tau disturbs mitocho drial bioenergetics by inhibiting Complex I activity,
decreasing the ∆Ψm and ATP levels, and increasing ROS production. These effects may also be linked to
abnormal tau impacts on the mPTP opening, and/ or to tau direct binding on mitochondrial proteins like
voltage-dependent anion channel (VDAC) and subunits on the respiratory Complex V. (5) Abnormal tau
disturbs mitochondrial steroidogenesis by decreasing pregnenolone synthesis. Finally, abnormal tau seems
to impact on the ER-mitochondrial coupling, which may have consequences on all the above mentioned
mitochondrial functions. ANT: adenine nucleotide translocator, ATP: adenosine triphosphate, CI-CV:
respiratory complexes I–V, CypD: cyclophilin D, DRP1: dynamin-related protein 1, ER: endoplasmic
reticulum, ETC: electron transport chain, GRP75: glucose-related protein 75, IP3R: inositol 3 phosphate
receptor, JIP1: c-Jun N-terminal kinase-interacting protein 1, MFN1/ 2: mitofusin 1/ 2, mPTP: mitochondrial
permeability transition pore, OPA1: optic atrophy 1, P450scc: cytochrome P450 cholesterol side-chain
cleavage enzyme, ROS: reactive oxygen species, TSPO: translocator protein, VDAC: voltage-dependent
anion channel, ∆Ψm: mitochondrial membrane potential.
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4.1. Mitochondrial Transport
Being a member of the family of MAPs, tau is involved in the transport of cargoes along the
axons, including mitochondria. In K3 mice expressing the K369I tau mutation, anterograde axonal
transport of mitochondria was impaired, reducing the number of mitochondria at the synapse [119].
Synaptic mitochondria play important roles in calcium buffering and fulfill the high energy required in
this cellular compartment. Therefore, a decrease in mitochondrial transport to the synapse may lead
to synaptic degeneration and neuronal death [106]. One proposed mechanism is that abnormal tau
interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1), which is associated with the kinesin
motor protein complex [134]. By sequestrating JIP1 in the cell body, abnormal tau impairs its transport
to the axon, which disturbs the formation of the kinesin motor complex and impacts the kinesin-driven
anterograde transport of mitochondria [119,134]. Of note, because abnormal tau leads to microtubule
disassembly [135], it is not excluded that impairing the axonal microtubule tracks for the transport of
cargoes impacts mitochondrial transport. Conversely, knockdown of Milton or Miro that are adaptor
proteins involved in the axonal transport of mitochondria enhanced tau phosphorylation in transgenic
Drosophila expressing human tau in a process involving partitioning defective-1 (PAR-1) protein and
leading to neurodegeneration [136]. This indicates that a loss of axonal mitochondria promotes tau
phosphorylation and neuronal degeneration. In PC12 cells and cortical mouse neurons, abnormal
tau was shown to inhibit mitochondrial movement in the neurite processes [121]. In this model,
abnormal tau did not disturb the interaction between kinesin and microtubules, but caused an increase
in the inter-microtubular distance, affecting mitochondrial movement and velocity. In line, a decrease
in mitochondrial content in the neurites was quantified in neurons from rTg4510 mice expressing
the P301L tau mutation, paralleled with a perinuclear clustering of mitochondria [120]. Similarly,
a 50% reduction in the number of mitochondria was observed in the axons of P301L tau knock-in
mice (KI-P301L), which express the tau mutation at physiological levels [122]. Interestingly, in this
model, P301L tau was found to be hypophosphorylated, indicating that defects in axonal transport
may not be due to tau abnormal hyperphosphorylation. However, KI-P301L mice presented an
increased volume of motile axonal mitochondria as well as impairments in tau binding on microtubules,
which may disturb mitochondrial transport. Similar observations were made in SH-SY5Y cells stably
overexpressing the wild-type (hTau40) and mutant (P301L) form of tau [127]. Cells bearing the mutant
form of tau presented a decreased mitochondrial movement, abnormal mitochondrial morphology
(cristae with globular structures and branched membranes), a clustering of mitochondria around the
nucleus, as well as decreased fusion/ fission rates compared to wild-type tau expressing cells.
Impairments in mitochondrial axonal transport were also evident in induced pluripotent stem cells
(IPSCs) derived from frontotemporal dementia (FTD) patients bearing the R406W tau mutation [124].
In these IPSCs induced into cerebral organoids, axonal mitochondria were less stationary and moved
more in the retrograde direction, resulting in fewer mitochondria into the axon when compared to
control cells. In line, anterograde axonal transport of mitochondria was significantly reduced in
IPSC-derived neurons bearing the N279K and P301L tau mutation compared to controls [123].
Taken together, these findings show that abnormal tau affects the axonal transport of mitochondria,
decreasing the number of mitochondria at the synapse, which may lead to synaptic degeneration.
4.2. Mitochondrial Dynamics
Mutant tau protein was shown to impair mitochondrial dynamics in vivo in Drosophila expressing
human R406W tau as well as rTg4510 and K3 mice, leading to the elongation of the mitochondrial
network [125]. This may be involved in the reduced mitochondrial mobility and transport, as elongated
mitochondria are not easily transported, especially along the axon. One proposed mechanism is
that F-actin stabilization is increased in the presence of tau, disturbing the physical association of
DRP1 and mitochondria, leading to DRP1 mislocalization, excessive mitochondrial elongation and
subsequent neurotoxicity. These findings were reproduced in a recent study showing that increased
levels of leucine-rich repeat kinase 2 (LRRK2), which is involved in PD, enhanced tau neurotoxicity by
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stabilizing the actin cytoskeleton, promoting DRP1 mislocalization and mitochondrial elongation [137].
Interestingly, mitochondrial elongation was already observed at the early stages of tau pathology in
THY-Tau22 mice, when hippocampal Ca1 neurons are enriched with tau oligomers [138]. In these
mice, DRP1 levels were significantly decreased at six months of age compared to age-matched
wild-type littermates, whereas no differences were observed at 12 months of age. Another study
demonstrated that human wild-type tau (htau) overexpression disrupts mitochondrial dynamics and
causes mitochondrial elongation by increasing fusion proteins OPA1, and MFN1/ 2, which decreases
neuronal viability [126]. MFN2 knockdown reduced the htau-enhanced mitochondrial fusion and
restored mitochondrial function, indicating that mitofusin-associated mitochondrial fusion may play a
role in tau toxicity.
Intriguingly, expression of caspase-cleaved tau in immortalized cortical neurons, as well as in
cortical neurons from tau-/- knockout mice, induced mitochondrial fragmentation paralleled with a
decrease of OPA1 levels [139]. This indicates that abnormal tau phosphorylation and tau truncation
may impair mitochondrial dynamics via distinct mechanisms that still need to be unraveled.
4.3. Mitochondrial Bioenergetics
Tau-induced bioenergetic deficits were first observed in pR5 mice (P301L tau mutant mice),
in which proteomic analysis revealed a downregulation of subunits of the mitochondrial Complexes
I and V, together with an age-dependent decrease in mitochondrial respiration, Complex I activity
and ATP levels, as well as an increase in ROS when compared to wild-type littermates [128,129].
These findings were recapitulated in vitro in SH-SY5Y cells overexpressing P301L tau (P301L cells) [127].
In addition, P301L cells presented a decrease in the maximal respiration and in the spare respiratory
capacity, as well as a decrease in the ∆Ψm when compared to wild-type tau overexpressing cells [130].
These data may be explained by the inhibition of Complex I activity induced by abnormal tau. In line,
htau overexpression impaired mitochondrial bioenergetics by decreasing mitochondrial Complex I
activity, ATP levels, as well as the ATP/ ADP ratio in HEK293 cells and hippocampus of htau
mice compared to wild-type [126]. Interestingly, the genetic ablation of tau (tau-/-) significantly
improved the bioenergetics capacity of mitochondria and reduced the oxidative damages in the
hippocampus of young (three months old) mice, compared to age-matched wild-type littermates [132].
These improvements were paralleled with an increase in attentive capacity and exploratory ability
in tau-/- mice, suggesting that preventing tau abnormal modifications enhances mitochondrial and
brain functions.
A decrease in mitochondrial Complex I activity was also observed in the brain of rTg4510 mice,
but was surprisingly paralleled with an increase in ∆Ψm [140]. This feature was recapitulated in an
advanced human neuronal model: IPSCs-derived neurons from FTDP-17 patients carrying the 10+16
mutation [141]. Compared to control IPSCs, FTDP-17 neurons presented a decrease in Complex I activity
as well as in OXPHOS-derived ATP production, but an increased ∆Ψm. One proposed mechanism is
that hyperpolarization of mitochondria is due to Complex V working in reverse, leading to an increase
in ROS production, oxidative stress and cell death.
Conversely, a recent report showed that tau decreases the ∆Ψm via mitochondrial membrane
poration, which compromised organelle structural integrity, leading to the swelling of mitochondria [142].
In this study, mitochondria were isolated from SH-SY5Y neuroblastoma cells and treated with tau
oligomers. The decrease in ∆Ψm was coupled with a release of cytochrome c. Intriguingly, the effects
were independent of the mitochondrial permeability transition pore opening (mPTP), but rather due to
the formation of non-selective ion-conducting tau nanopores caused by the binding of oligomeric
tau on cardiolipin-rich membrane domains. These new data bring further insights into tau-induced
mitochondrial toxicity.
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4.4. Mitochondrial Permeability Transition Pore
The mPTP is a key contributor to cell death and has been involved in the pathophysiology of
several neurodegenerative diseases [143]. Indeed, upon mPTP opening, mitochondrial membranes
become permeable, disrupting mitochondrial function and releasing apoptotic signals into the cytosol.
The exact composition of the mPTP remains elusive, but several reports suggested that it comprises
proteins like voltage-dependent anion channel (VDAC) and translocator protein (TSPO) in the OMM,
adenine nucleotide translocator (ANT) in the IMM, and cyclophilin D (CypD) in the mitochondrial
matrix (reviewed in [143]). As abnormal tau was shown to disturb the ∆Ψm in several models (see the
previous section), one can suggest that these effects may be mediated by tau impacts on the mPTP.
Indeed, tau ablation inhibited mPTP formation in the hippocampus of three-months-old tau-/- mice
by reducing the CypD protein level, compared to wild-type littermates [132]. Besides, tau was shown
to directly interact with mitochondrial proteins, including subunits of the mitochondrial Complex V,
which might explain bioenergetic deficits induced by abnormal tau, and VDAC [144]. In particular,
phospho-tau interaction with VDAC was evident in the brain of AD patients at different Braak stages
(I to V), as well as in 13-months-old APP/PS1 and 3xTgAD transgenic mice [145]. Furthermore, in our
recent study, we showed that TSPO ligands increased the ∆Ψm in htau- and P301L tau-overexpressing
SH-SY5Y cells [131]. We speculated that this effect was mediated by the ability of these ligands to
modulate the mPTP, although further investigations need to be conducted to determine the exact
underlying mechanisms.
4.5. Mitophagy
Mitophagy plays a paramount role in mitochondrial quality control, by removing damaged
mitochondria and ensuring a healthy mitochondrial population. In primary cultures of hippocampal
neurons, the human 20–22 kDa NH2-tau fragment (NH2htau fragment mapping between 26 and
230 amino acids of the longest human tau isoform) was shown to increase mitophagic flux by recruiting
Parkin to mitochondria, correlating with a decrease of synaptic stability [146,147], a feature also observed
in human synaptic mitochondria from AD patients. In neurons expressing NH2htau, mitophagy
inhibition partially prevented NH2htau-induced synaptic degeneration and neuronal death [147].
Other studies focusing on tau overexpression models showed that abnormal tau inhibits
mitophagy [117,133]. Strikingly, an increase in the mitochondrial DNA/nuclear DNA ratio, as well as
in mitophagy markers (COX IV and TOMM20), were observed in the brain of tau-positive AD patients,
compared to tau-negative patients and healthy controls [133]. These data were recapitulated in vivo
in htau transgenic mice, as well as in vitro in HEK293 and primary neurons overexpressing htau.
In this study, htau overexpression induced an increase in the ∆Ψm, preventing the recruitment of PINK/
Parkin to the mitochondrial fraction. Mitophagy deficits were rescued after Parkin overexpression
in htau-overexpressing H293 cells. In line, using mitophagy reporters, Cummins and colleagues
showed that both htau and P301L tau inhibited mitophagy in N2a cells and Caenorhabditis elegans [117].
Unlike the study previously described [137], the effects of tau on mitophagy were not due to changes
in the ∆Ψm, but to the sequestration of Parkin in the cytosol via interaction with the projection domain
of tau. This sequestration prevented the recruitment of Parkin to mitochondria, inhibiting mitophagy.
Interestingly, mitophagy stimulation reduced tau hyperphosphorylation in vitro (SH-SY5Y cells
overexpressing 2N4R, 1N4R, 2N3R tau) and in vivo (transgenic nematodes expressing human tau and
3xTgAD mice), and reversed memory impairment in transgenic animals [86].
Together, these findings indicate that impaired mitophagy plays a role in tau pathogenesis,
and highlight again distinct pathological features between models of tau phosphorylation and
tau truncation.
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5. New Insight on the Impact of Abnormal Tau on Neurosteroidogenesis and the
ER-Mitochondria Coupling
5.1. Abnormal Tau and Neurosteroids
We recently showed that abnormal tau also disturbs another mitochondrial function: the synthesis
of neurosteroids or neurosteroidogenesis [131]. Indeed, steroids can be synthesized de novo in the
brain from cholesterol, independently of the peripheral steroidogenic glands, and are then called
“neuro”-steroids (reviewed in [148]). The first step of steroidogenesis takes place in mitochondria
with the transfer of cholesterol from the cytosol to the mitochondrial matrix, and its conversion
to pregnenolone (PREG), the precursor of all neurosteroids. PREG is then converted into other
neurosteroids either in mitochondria or in the ER. In the nervous system, neurosteroids play important
roles in the regulation of neuronal functions as they can act as allosteric modulators of neurotransmitter
receptors (e.g., NMDA or GABA receptors) [149].
Decreased levels of neurosteroids were observed in AD brains [150–152]. In particular, the levels
of the neurosteroids pregnenolone sulfate (PREGS) and dehydroepiandrosterone sulfate (DHEAS)
were significantly reduced in the striatum, hypothalamus and cerebellum of AD patients compared to
non-demented controls (postmortem analysis) [150]. Lower levels of PREG, dehydroepiandrosterone
(DHEA), as well as PREGS and DHEAS, were also observed in the hippocampus, amygdala and
frontal cortex of AD patients, and were negatively correlated with the presence of NFTs. Interestingly,
another study showed that the neurosteroid allopregnanolone is reduced in the prefrontal cortex,
and is inversely correlated with the patient’s Braak stage, which reflects the evolution of tau
pathology [151]. Together, these findings suggest a relationship between tau pathology, neurosteroids
levels, and cognitive deficits, but the exact link remains elusive.
In our recent study, we showed that PREG levels were decreased in htau-overexpressing SH-SY5Y
cells, and even more significantly reduced in P301L cells [131]. This effect was normalized in
cells treated with TSPO ligands, which is involved in the first step of neurosteroidogenesis in
mitochondria. The underlying mechanisms are currently under investigation in our laboratory.
Nevertheless, we previously showed that neurosteroids, such as progesterone, estradiol, testosterone,
DHEA and allopregnanolone, increase bioenergetics via the improvement of ATP production and
mitochondrial respiration, and regulate the redox homeostasis in neuronal cells [153,154]. In particular,
abnormal tau-induced mitochondrial impairments were reduced after treatment with progesterone,
estradiol and testosterone [130].
Neuroprotective effects of a treatment with neurosteroids or sex-hormones-derived neuroactive
steroids were evident against cognitive and bioenergetics deficits observed in AD (reviewed in [99,155]).
In particular, allopregnanolone induces neurogenesis, restores learning and memory function, shows a
trend to decrease phospho-tau levels, and reverses bioenergetic deficits in 3xTgAD transgenic
mice [155–158]. Allopregnanolone is currently undergoing clinical trials for the treatment of AD [159].
As the effects of neurosteroids in other tauopathies are less studied and remain elusive, the use
of these molecules as therapeutic agents against abnormal tau-induced neurodegeneration would
deserve more attention in future investigations.
5.2. Abnormal Tau and ER-Mitochondria Coupling
Mitochondria are closely connected to ER membranes, forming a highly dynamic platform termed
as mitochondria-associated ER membranes (MAMs). Particularly, up to 20% of the mitochondrial
surface associates with ER membranes, allowing tight communication physically and biochemically.
Accordingly, MAMs provide an outstanding scaffold for the crosstalk between mitochondria and
the ER, playing a crucial role in different signaling pathways that require a rapid exchange of
metabolites for the maintenance of cellular health. Moreover, numerous proteins have been revealed
to be enriched in MAMs, participating in the regulation of many fundamental cellular pathways.
Therefore, MAM crosstalk is involved in a variety of processes, including cholesterol metabolism,
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calcium homeostasis, phospholipid metabolism, the transfer of lipids between these two organelles,
and the regulation of mitochondrial bioenergetics and dynamics. Besides, MAM coupling affects
autophagy, ER-stress, inflammation and finally apoptosis [160–163]. In view of contributing to so
many functions, it is hardly surprising that MAMs have drawn great attention in the studying of
cell homeostasis and dysfunction, especially in the context of neurodegenerative disaeses. Strikingly,
an increasing number of disease-associated proteins have been demonstrated to interact with MAMs,
thereby regionally inducing structural and functional perturbations [164].
Mounting evidence emphasizes the role of a disturbed ER-mitochondria interconnection in
neurodegenerative diseases such as AD, FTD and amyotrophic lateral sclerosis (ALS) (reviewed in [161]).
For instance, in Aβ-related AD models, impairments in the ER-mitochondria coupling are translated
by: (i) an increase in the expression of MAMs proteins and in the number ER-mitochondria
contact points [165]; (ii) an upregulation in MAMs function including phospholipid and cholesterol
synthesis [165,166]; and (iii) disturbed calcium homeostasis triggering a pathological cascade of
events leading to apoptosis [160,167]. In amyotrophic lateral sclerosis with associated frontotemporal
dementia (ALS/ FTD), TAR DNA-binding protein 43 (TDP-43) was shown to loosen ER–mitochondria
contacts by disturbing the link between vesicle-associated membrane protein-associated protein B
(VAPB) at the ER membrane and protein tyrosine phosphatase interacting protein 51 (PTPIP51) at the
mitochondrial membrane, two proteins involved in MAMs tethering [161,168]. This disruption of the
ER-mitochondria interaction disturbed the calcium exchange between both organelles, and may be
linked to the decrease in ATP levels leading to motor neuron degeneration [168,169].
Until recently, only one study had focused on the impact of abnormal tau on the ER-mitochondria
interaction [170]. Indeed, using electron microscopy techniques, Perreault and colleagues showed a
higher number of ER-mitochondria contact points in a tau transgenic mouse model (JNPL3, P301L tau
transgenic mice) compared to wild-type animals. An increased association of hyperphosphorylated
tau with ER membranes was also observed in post-mortem brains of AD patients, suggesting that
the ER-mitochondria axis may also play a role in abnormal tau-induced neurodegeneration. In line,
Cieri et al. showed that overexpression of caspase 3-cleaved 2N4R∆C20 tau in Hela cells increased the
number of tight (8–10 nm) ER-mitochondria contact points, whereas long-range (40–50 nm) interactions
were not affected [171]. In parallel, truncated (2N4R∆C20) and full length (2N4R) tau expression affected
the ER calcium storage, suggesting that tau may disturb the MAMs leading to ER calcium mishandling.
Interestingly, tau was also found at the OMM and within the IMS, but not in the mitochondrial matrix.
With the aim to characterize the link between ER-stress and bioenergetic defects in the presence of
tau, we recently showed that P301L expressing SH-SY5Y cells presented a highly activated unfolded
protein response (UPR = ER-stress) and dysregulated mitochondrial bioenergetics in basal condition,
when compared to wtTau cells [172]. Furthermore, acute ER-stress was induced using thapsigargin,
which increased the activity of the UPR in both wtTau and P301L tau cells, leading to the upregulation
of apoptotic pathways, and further dysregulated mitochondrial function. This study supports the role
of close communication between mitochondria and the ER during apoptosis in tauopathies.
Further investigations are now needed to unravel the underlying mechanisms, as well as
potential effects of abnormal tau on other MAM functions (e.g., cholesterol and phospholipid
homeostasis), which may highlight potential therapeutic targets. For instance, in ALS/ FTD, TDP-43
was shown to induce the activation of GSK 3β, which then disrupts the binding of PTPIP51 and
VAPB (reviewed in [161]). Since GSK 3β is also involved in tau phosphorylation and is up-regulated
in AD [173,174], it constitutes a good candidate against tauopathies. However, whether GSK 3β is
involved in impairments of the ER-mitochondria coupling in abnormal tau-related diseases remains to
be determined.
6. Conclusions
In summary, abnormal tau has an impact on all aspects of mitochondrial functions, from mitochondrial
transport and dynamics, to bioenergetics and mitophagy (Figures 3 and 4). Because mitochondria
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play a pivotal role in neuron life and death [1], alteration in their function leads to neuronal
dysfunction and death, and eventually to dementia. Besides, given that mitochondria are not
isolated, self-autonomous organelles floating in the cytosol, but on the contrary highly interconnected
with other cellular compartments, including the ER, it is not surprising that abnormal tau-induced
mitochondrial dysfunction affects other cellular functions, and vice versa. It is, however, important
to note that discrepancies are sometimes observed between tau models. Common features were
observed with regards to mitochondrial bioenergetics (decreased ATP levels, Complex I inhibition)
and transport (impaired axonal transport, perinuclear clustering), but different findings were obtained
concerning the ∆Ψm (increased or decreased ∆Ψm in the presence of tau), mitochondrial dynamics
(tau-induced mitochondrial elongation or fragmentation) and mitophagy (triggered or inhibited
by tau). Strikingly, these differences are often linked with the type of tau used in the study
(phospho-tau or truncated tau). These two aspects of tau pathology should be considered to fully
understand the molecular mechanisms underlying tauopathies, and are therefore important to highlight
therapeutic targets.
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PINK1 PTEN-induced kinase 1
PKA cAMP-dependent protein kinase A
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TOMM20 translocase of outer mitochondrial membrane 20
TSPO translocator protein
TTBK1/ 2 tau-tubulin kinase 1/ 2
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